Company description

Supernus Pharmaceuticals Inc. (SUPN) is a publicly listed pharmaceutical company headquartered in Rockville, Maryland. The company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases, including rare and hard-to-treat conditions. With a strong commitment to innovation, Supernus has continuously expanded its portfolio and pipeline, resulting in significant growth and success. The company's flagship products include Oxtellar XR, a treatment for partial-onset seizures in adults and adolescents, and Trokendi XR, a treatment for both partial and primary generalized tonic-clonic seizures. Both drugs have gained FDA approval and have shown significant efficacy and safety in clinical trials. In addition to its current products, Supernus is also dedicated to advancing its pipeline, with several potential treatments for CNS disorders in various stages of development. The company has a diversified and experienced management team, with a focus on building strategic partnerships and collaborations to further expand its reach and market presence. With a strong emphasis on research and development, combined with its successful commercialization track record, Supernus Pharmaceuticals Inc. is well-positioned for continued growth and success in the highly competitive pharmaceutical industry.